Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival

Carcinogenesis

Volumn 28, Issue 2, 2007, Pages 372-377

  Li, Hongxia ^a   Yao, Lihua ^a   Ouyang, Tao ^a   Li, Jinfeng ^a   Wang, Tianfeng ^a   Fan, Zhaoqing ^a   Fan, Tie ^a   Dong, Bin ^a   Lin, Benyao ^a   Li, Jiyou ^a   Xie, Yuntao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYSTEINE; DOXORUBICIN; FLUOROURACIL; GENOMIC DNA; GLYCINE; METHOTREXATE; PROTEIN P73; TAMOXIFEN; THREONINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOTE; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL TIME;

BASE SEQUENCE; BREAST NEOPLASMS; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 33847294804     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl153     Document Type: Article

References (38)

1. Gao,Y.T., Shu,X.O., Dai,Q. et al. (2000) Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai Breast Cancer Study. Int. J. Cancer, 87, 295-300.
2. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet, 352, 930-942.
3. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet, 351, 1451-1467.
4. Kaghad,M., Bonnet,H., Yang,A. et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90, 809-819.
5. Melino,G., De Laurenzi,V. and Vousden,KH. (2002) p73: Friend or foe in tumorígenesis. Nat. Rev. Cancer, 2, 605-615.
6. Jost,C.A., Marin,M.C. and Kaelin,W.G.,Jr. (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature, 389, 191-194.
7. Ichimiya,S., Nimura,Y., Kageyama,H. et al, (2001) Genetic analysis of p73 localized at chromosome 1p36.3 in primary neuroblastomas. Med. Pediatr. Oncol., 36, 42-44.
8. Ahomadegbe,J.C., Tourpin,S., Kaghad,M. et al. (2000) Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers. Oncogene, 19, 5413-5418.
9. Nomoto,S., Haruki,N., Kondo,M., Konishi,H. and Takahashi,T. (1998) Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res., 58, 1380-1383.
10. Zhu,J., Jiang,J., Zhou,W. and Chen,X. (1998) The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res., 58, 5061-5065.
11. Yang,A., Walker,N., Bronson,R. et al. (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature, 404, 99-103.
12. Benard,J., Douc-Rasy,S. and Ahomadegbe,J.C. (2003) TP53 family members and human cancers. Hum. Mutat., 21, 182-191.
13. Zaika,A.I., Slade,N., Erster,S.H., Sansome,C., Joseph,T.W., Pearl,M., Chalas,E. and Moll,U.M. (2002) DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med, 196, 765-780.
14. Stiewe,T., Zimmermann,S., Frilling,A., Esche,H. and Putzer,B.M. (2002) Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res., 62, 3598-3602.
15. Grob,T.J., Novak,U., Maisse,C. et al. (2001) Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ., 8, 1213-1223.
16. Ishimoto,O., Kawahara,C., Enjo,K., Obinata,M., Nukiwa,T. and Ikawa,S. (2002) Possible oncogenic potential of DeltaNp73: A newly identified isoform of human p73. Cancer Res., 62, 636-641.
17. Fillippovich,I., Sorokina,N., Gatei,M. et al. (2001) Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene, 20, 514-522.
18. Uramoto,H., Sugio,K., Oyama,T., Nakata,S., Ono,K., Morita,M., Funa,K. and Yasumoto,K. (2004) Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin. Cancer Res., 10, 6905-6911.
19. Douc-Rasy,S., Barrois,M., Echeynne,M. et al. (2002) DeltaN-p73alpha accumulates in human neuroblastic tumors. Am. J. Pathol., 160, 631-639.
20. Casciano,I., Mazzocco,K., Boni,L., Pagnan,G., Banelli,B., Allemanni,G., Ponzoni,M., Tonini,G.P. and Romani,M. (2002) Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ., 9, 246-251.
21. Pfeifer,D., Arbman,G. and Sun,X.F. (2005) Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis, 26, 103-107.
22. Niwa,Y., Hirose,K., Matsuo,K., Tajima,K., Ikoma,Y., Nakanishi,T., Nawa,A., Kuzuya,K., Tamakoshi,A. and Hamajima,N. (2005) Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett, 219, 183-190.
23. Hu,Z., Miao,X., Ma,H., Tan,W., Wang,X., Lu,D., Wei,Q., Lin,D. and Shen,H. (2005) Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int. J. Cancer, 114, 455-460.
24. Niwa,Y., Hamajima,N., Atsuta,Y. et al. (2004) Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett., 205, 55-60.
25. Li,G., Sturgis,E.M., Wang,L.E., Chamberlain,R.M., Amos,C.I., Spitz,M.R., El-Naggar,A.K., Hong,W.K. and Wei,Q. (2004) Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 25, 1911-1916.
26. Li,G., Wang,L.E., Chamberlain,R.M., Amos,C.I., Spitz,M.R. and Wei,Q. (2004) p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res., 64, 6863-6866.
27. Hishida,A., Matsuo,K., Tajima,K., Ogura,M., Kagami,Y., Taji,H., Morishima,Y., Emi,N., Naoe,T. and Hamajima,N. (2004) Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p2l Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk Lymphoma, 45, 957-964.
28. Ryan,B.M., McManus,R., Daly,J.S., Carton,E., Keeling,P.W., Reynolds,J.V. and Kelleher,D. (2001) A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br. J. Cancer, 95, 1499-1503.
29. Nowell,S., Sweeney,C., Winters,M., Stone,A., Lang,N.P., Hutchins,L.F., Kadlubar,F.F. and Ambrosone,C.B. (2002) Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J. Natl Cancer Inst., 94, 1635-1640.
30. Bonafe,M., Ceccarelli,C., Farabegoli,F. et al. (2003) Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin. Cancer Res., 9, 4860-4864.
31. Keyomarsi,K., Tucker,S.L., Buchholz,T.A. et al. (2002) Cyclin E and survival in patients with breast cancer. N. Engl. J. Med, 347, 1566-1575.
32. Huang,X.E., Hamajima,N., Katsuda,N. et al. (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer, 10, 307-311.
33. Hiraki,A., Matsuo,K., Hamajima,N., Ito,H., Hatooka,S., Suyama,M., Mitsudomi,T. and Tajima,K. (2003) Different risk relations with smoking for non-small-cell lung cancer: Comparison of TP53 and TP73 genotypes. Asian Pac. J. Cancer Prev., 4, 107-112.
34. Mai,M., Qian,C., Yokomizo,A., Tindall,D.J., Bostwick,D., Polychronakos,C., Smith,D.I. and Liu,W. (1998) Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene, 17, 1739-1741.
35. Mai,M., Yokomizo,A., Qian,C., Yang,P., Tindall,D.J., Smith,D.I., and Liu,W. (1998) Activation of p73 silent allele in lung cancer. Cancer Res., 58, 2347-2349.
36. Chi,S.G., Chang,S.G., Lee,S.J., Lee,C.H., Kim,J.I. and Park,J.H. (1999) Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer. Cancer Res., 59, 2791-2793.
37. Takahashi,H., Ichimiya,S., Nimura,Y., Watanabe,M., Furusato,M., Wakui,S., Yatani,R., Aizawa,S. and Nakagawara,A. (1998) Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res., 58, 2076-2077.
38. Muller,M., Schilling,T., Sayan,A.E. et al. (2005) TAp73/DeltaNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ.